Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia

By sjmartinez • October 7, 2023

Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, Kennedy VE, Khanna V, Olmedo Gutierrez K, Shukla N, Moskoff B, Park G, Afkhami M, Patel A, Jeyakumar D, Mannis G, Logan AC, Jonas BA, Schiller G. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2023 Oct 6:1-9. doi: 10.1080/10428194.2023.2264426. Epub ahead of print. PMID: 37801340.

Tags: Acute myeloid leukemia, allogeneic hematopoietic stem cell transplantation, consolidation chemotherapy, fellows, General Internal Medicine, Hematology/Oncology, measurable residual disease, Publications, Resident

A Unique Case of a Mildly Symptomatic Patient With Severe Hypokalemia Secondary to Furosemide

Dao KT, Dhillon A, Uddin SS, Eppanapally S, Lai H. A Unique Case of a Mildly Symptomatic Patient With Severe Hypokalemia Secondary to Furosemide. J[...]

Advancements in Spinal Cord Injury Rehabilitation

Eapen BC. Advancements in Spinal Cord Injury Rehabilitation. Phys Med Rehabil Clin N Am. 2025 Feb;36(1):xiii-xiv. doi: 10.1016/j.pmr.2024.09.002. Epub 2024 Oct 18. PMID: 39567042.

Higher-order disease interactions in multimorbidity measurement: marginal benefit over additive disease summation

Wei MY, Tseng CH, Kang AJ. Higher-order disease interactions in multimorbidity measurement: marginal benefit over additive disease summation. J Gerontol A Biol Sci Med Sci.[...]